This article is more than 5 years old. Information may no longer be current.
Promethera Biosciences acquires Baliopharm, develops therapeutic strategies for NASH
Click Here to Manage Email Alerts
Promethera Biosciences SA, a company specializing in cell-based medicines and liver disease, announced the acquisition of Baliopharm AG, a biopharmaceutical company concentrated on biological therapies for immune-mediated inflammatory disease and cancer.
“The acquisition of Baliopharm immediately adds very promising antibody assets to our cell-based pipeline and diversifies our therapeutic strategy in NASH by giving us a proprietary combination therapy option,” John Tchelingerian, MD, Promethera Biosciences SA president and CEO, said in a press release.
This purchase has allowed Promethera to gain control of Baliopharm’s antibody development programs, such as its antibody monovalent drug candidate, Atrosimab, according to the release. Atrosimab binds to tumor necrosis factor receptor 1 (TNF-R1) and will likely be combined with Promethera’s liver cell-based therapies, like its HepaStem technology, to potentially improve treatment options for patients with nonalcoholic steatohepatitis (NASH) and other sever liver diseases.
“Promethera is well positioned to advance the development of Atrosimab and explore unique combination strategies which could offer NASH patients a superior treatment option in future,” Andreas Herrmann, MD, CEO of Baliopharm, said in the release.
Disclosures: Tchelingerian is employed by Promethera and Herrmann is employed by Baliopharm.